[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Wegro App @wegro_app on x 10.3K followers
Created: 2025-07-16 12:23:58 UTC
𝗦𝗮𝗻𝗼𝗳𝗶 𝗜𝗻𝗱𝗶𝗮: 𝗞𝗲𝘆 𝗕𝗼𝗮𝗿𝗱 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽
Sanofi India announced significant changes and a new partnership following a board meeting held on July 16, 2025. 🗓️ The company appointed Mr. Rachid Ayari, the current CFO, as the Interim Managing Director for a term of six months, starting July 21, 2025. Additionally, Mr. Aniket Raje has been appointed as the Head of Regulatory Affairs, effective August 1, 2025. A notable development is the exclusive distribution and promotion agreement with Emcure Pharmaceuticals for Sanofi's oral anti-diabetic drugs. 💊
𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗖𝗵𝗮𝗻𝗴𝗲𝘀: ▪ Mr. Rachid Ayari appointed as Interim Managing Director for X months (July 21, 2025 - January 20, 2026). He will continue in his role as CFO. 💼 ▪ Mr. Aniket Raje appointed as Head of Regulatory Affairs, effective August 1, 2025. 👨💼
𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽: ▪ Exclusive distribution and promotion agreement with Emcure Pharmaceuticals for Sanofi's oral anti-diabetic products. 🤝 ▪ Agreement effective immediately for an initial period of X years. ⏳ ▪ Sanofi will continue to manufacture the products. 🏭 ▪ Emcure will focus on engaging healthcare professionals and expanding the reach of these products. 🌍
This strategic move aims to broaden the reach of Sanofi's oral anti-diabetic medications in India. 🇮🇳
📊 SANOFI INDIA LTD | 🏷️ Press Release / Media Release
🌐 Details:
⚡️AI-driven WhatsApp updates - Try FREE 👉
XXX engagements
Related Topics india sanofi stocks healthcare